» Articles » PMID: 15313897

Altered DNA Polymerase Iota Expression in Breast Cancer Cells Leads to a Reduction in DNA Replication Fidelity and a Higher Rate of Mutagenesis

Overview
Journal Cancer Res
Specialty Oncology
Date 2004 Aug 18
PMID 15313897
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

The recently discovered human enzyme DNA polymerase iota (pol iota) has been shown to have an exceptionally high error rate on artificial DNA templates. Although there is a considerable body of in vitro evidence for a role for pol iota in DNA lesion bypass, there is no in vivo evidence to confirm this action. We report here that pol iota expression is elevated in breast cancer cells and correlates with a significant decrease in DNA replication fidelity. We also demonstrate that UV treatment of breast cancer cells additionally increases pol iota expression with a peak occurring between 30 min and 2 h after cellular insult. This implies that the change in pol iota expression is an early event after UV-mediated DNA damage. That pol iota may play a role in the higher mutation frequencies observed in breast cancer cells was suggested when a reduction in mutation frequency was found after pol iota was immunodepleted from nuclear extracts of the cells. Analysis of the UV-induced mutation spectra revealed that > 90% were point mutations. The analysis also demonstrated a decreased C --> T nucleotide transition and an increased C --> A transversion rate. Overall, our data strongly suggest that pol iota may be involved in the generation of both increased spontaneous and translesion mutations during DNA replication in breast cancer cells, thereby contributing to the accumulation of genetic damage.

Citing Articles

Implications of Translesion DNA Synthesis Polymerases on Genomic Stability and Human Health.

Venkadakrishnan J, Lahane G, Dhar A, Xiao W, Bhat K, Pandita T Mol Cell Biol. 2023; 43(8):401-425.

PMID: 37439479 PMC: 10448981. DOI: 10.1080/10985549.2023.2224199.


Leveraging the replication stress response to optimize cancer therapy.

Cybulla E, Vindigni A Nat Rev Cancer. 2022; 23(1):6-24.

PMID: 36323800 PMC: 9789215. DOI: 10.1038/s41568-022-00518-6.


Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses.

Heitmeir B, Deniz M, Janni W, Rack B, Schochter F, Wiesmuller L Cancers (Basel). 2022; 14(4).

PMID: 35205744 PMC: 8869884. DOI: 10.3390/cancers14040997.


Probing altered enzyme activity in the biochemical characterization of cancer.

Ahmed Adam M, Sohl C Biosci Rep. 2022; 42(2).

PMID: 35048115 PMC: 8819661. DOI: 10.1042/BSR20212002.


Unravelling roles of error-prone DNA polymerases in shaping cancer genomes.

Vaziri C, Rogozin I, Gu Q, Wu D, Day T Oncogene. 2021; 40(48):6549-6565.

PMID: 34663880 PMC: 8639439. DOI: 10.1038/s41388-021-02032-9.